Monday, 22 December 2025
  
Login

Australia's most trusted
source of pharma news

Monday, 22 December 2025
News

Obesity funding arrives... with strings

Posted 22 December 2025 AM

The PBAC has delivered hopeful news to the 420,000 or so Australians using GLP-1s on private script, saying some populations would benefit from subsidised access and going so far as to recommend one in the same meeting. However, it added the PBS is not a viable path for "preventative" access.

Novo Nordisk's Wegovy has become the first obesity treatment to be recommended for subsidy on the PBS, seemingly fitting all the criteria the Committee raised in the advice it gave to the government on funding GLP-1 medications to treat obesity.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (11)

Clinical & Medical, R&D (10)

Devices (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.